Depression Flashcards

1
Q

what is depression?

A

Depression and mania are mood disorders (affective disorders)

Depressed mood and/or loss pleasure in activities are central to depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the definition of mood and affect?

A

In psychiatric terms:
Affect: an objective description of a person’s emotional behaviour
Mood: an individual’s prevailing subjective emotional state

Thus, mood disorders include illnesses with abnormally high or low mood, i.e. mania and depression.

Mood disorders broadly include:
Depression including its variants, bipolar disorder, dysthymia (subthreshold depression), cyclothymia…

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how can you Classify Mood/Affective Disorders
what is used for diagnosis ?

A

Typically based upon assessments of:
Severity
Presence or absence of physical (somatic/biological) features
Presence or absence of psychotic features
Course (duration and recurrence)
Presence or absence of intervening manic phases

Criteria used to diagnose:
UK: ICD-11/DSM-5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the aetiology of depression?

A

Brain regional changes:
Regions important for mood and other functions linked to depression

Genes and environment:
Family history is common in depression
Genetic and/or environmental components
Temperament/personality
Medical conditions and medications (as well as substance misuse)

Biochemical:
Reserpine (anti-hypertensive) a non-specific central amine depleter was reported to cause depression - controversial and has been disputed. Other drugs can cause depression (e.g. isotretinoin, interferon alpha)
Tricyclic anti-depressants prevent amine reuptake
Monoamine oxidase inhibitors act as effective antidepressants
Above evidence supports an ‘amine deficiency theory’ of depression, specifically 5-HT (serotonin) but not the only theory
AND there are no reliable metabolic or biochemical markers for depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Monoamine Neurotransmission
function ?

A

depletion in the levels of serotonin, norepinephrine, and/or dopamine in the central nervous system.

Noradrenaline (norepinephrine, NA, NE):
Energy, concentration, memory, fight or flight

Serotonin
(5-hydroxytryptamine, 5-HT):
Mood, impulse control, cognition, appetite

Dopamine:
Reward, pleasure, motivation, alertness, appetite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the diagnosis of depression?

A

Two main diagnostic criteria scales are used in diagnosis: DSM-V and ICD-11. [NICE guidance is based on these two sets of criteria – see later]

Patient must exhibit at least one key (core) symptoms: low mood and/or loss interest/pleasure and symptoms should have been present for most of the time, most days for at least 2 weeks accompanied by other specific symptoms

Not consistent with previous behaviour/personality and not secondary to other treatment

Depression questionnaires such as the Beck Depression Inventory II (BDI-II), Patient Health Questionnaire 9 (PHQ-9) or Hospital Anxiety and Depression scale (HADS) can be to aid the diagnosis, assess symptom severity, functioning (and also to assess treatment effects) – valid in primary care. Hamilton Depression Rating Scale (HAMD) is also used. For example, PHQ-9 is based on DSM-5 and scores each criterion out of 3 – to maximum of 27

Need assess severity of symptoms

But it’s all subjective

From current NICE guidance, HCPs need to: be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:
During the last month, have you often been bothered by feeling down, depressed or hopeless?
During the last month, have you often been bothered by having little interest or pleasure in doing things?
If patients answer yes to either of these, a HCP qualified to perform a mental health assessment for the patient should do so (or refer if necessary), preferably using a validated measure to do so
Current ICD-11 or Current DSM-5
Depression questionnaires can also be used in conjunction (e.g. HADS, BDI-II and PHQ-9)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is the difference between ICD-11 and DSV-5

A

DSM-5
Depressed mood most of the day, nearly every day
Marked diminished interest or pleasure in all or almost all activities most of the day, nearly every day
Fatigue / loss of energy nearly every day
Feelings of worthlessness or excessive or inappropriate guilt nearly every day
Recurrent thoughts of death, recurrent suicidal ideation without a specific plan or a suicide attempt or a specific plan for committing suicide
Diminished ability to think or concentrate or indecisiveness, nearly every day
Psychomotor agitation or retardation
Insomnia or hypersomnia nearly every day
Significant weight loss or gain or increase/decrease in appetite nearly every day

ICD-11
Depressed mood
Diminished interest or pleasure in activities
Reduced energy or fatigue
Hopelessness about the future
Beliefs of low self-worth or excessive or inappropriate guilt
Recurrent thoughts of death or suicidal ideation or evidence of attempted suicide
Reduced ability to concentrate and sustain attention or marked indecisiveness
Psychomotor agitation or retardation
Significantly disrupted sleep or excessive sleep
Significant changes in appetite or weight

DSM-V requires at least 5 out of 9 symptoms during same 2-week period with at least one core symptom
ICD-11 at least one core symptom most of the day nearly every day for at least 2 weeks plus other symptoms such as those listed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how to assess the severity?

A

Less severe encompasses sub-threshold and mild, score <16 on PHQ-9
More severe encompasses moderate and severe, score >16 on PHQ-9

Sub-threshold - 2+, <5, including 1 core

Severity- DSM-IV Major Depression- ICD-10 Depressive Episode
Mild - Minimal above minimum of 5 - 4
Moderate- Between mild and severe - 5-6
Severe- Several in excess of 5- 7+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the stepped care model?

A

STEP
Focus of Intervention
Nature of Intervention

step 4
- Severe and complex depression; risk to life; severe self-neglect
- Medication, high-intensity psychological interventions, ECT, crisis service, combined treatments, multi-professional and inpatient care

step 3
- Persistent subthreshold depressive symptoms or mild-to-moderate depression with inadequate response to initial interventions; moderate and severe depression
- Medication, high-intensity psychological interventions, combined treatments, collaborative care and referral for further assessment and interventions

step 2
- Persistent subthreshold depressive symptoms; mild-to-moderate depression
- Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions

step 1
-All known and suspected presentations of depression
-Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the matched care model

A

STEP
Focus of Intervention
Nature of Intervention

4
- Chronic depression, psychotic depression, depression with personality disorder
- Medication, high-intensity psychological interventions, ECT, crisis service, combined treatments, multi-professional and inpatient care

3
- More severe depression or less severe with limited response to initial interventions
- Medication, high or low-intensity psychological interventions, combined treatments

2
- Less severe depression
- High or low-intensity psychological and psychosocial interventions, medication

1
- All known and suspected presentations of depression
- Assessment, support, psychoeducation, active monitoring and referral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the Treatment Options Less SevereDepression: 2022

A

Options for Less Severe Depression, in order of recommendation:

1.Individual guided self-help
2.Group Cognitive Behavioural Therapy (CBT)
3.Group Behavioural activation (BA)
4. Individual CBT
5. Individual BA
6. Group exercise
7. Group mindfulness and meditation
8. Interpersonal psychotherapy (IPT)
9. SSRIs
10. Counselling
11. Short-term psychodynamic psychotherapy (STPP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the Treatment Options More SevereDepression: 2022

A

Options for More Severe Depression, in order of recommendation:

  1. Combined Individual CBT + antidepressant*
  2. Individual CBT
    3, Individual BA
  3. Antidepressant medication*
  4. Individual problem-solving
  5. Counselling
  6. Short-term psychodynamic psychotherapy (STPP)
  7. Interpersonal psychotherapy (IPT)
  8. Guided self-help
  9. Exercise

*Antidepressant medication: can be SSRI, SNRI or other AD indicated, based on clinical & treatment history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treating Depression: Antidepressants

A

Monoamine oxidase inhibitors (MAOIs)
Many dangerous side-effects, rarely
Used (sub-group called RIMAs safer)

Inhibitors of monoamine uptake
e.g. Selective Serotonin
Reuptake Inhibitors (SSRIs)
[as well as SNRIs, NRIs – see later]
and tricyclics (TCAs)

Modulators of serotonin (5HT) receptors and other NT receptors
e.g. NaSSa, SMS and others (next slide)

St John’s Wort
Unknown MoA, may be problematic due to effects upon hepatic enzyme activity, OTC but unlicensed and many interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Antidepressants: Inhibitors of monoamine uptake
Tricyclics (TCAs):
drug class
examples
side effects

A

Tricyclics (TCAs): were used before SSRIs

e.g. imipramine, clomipramine, lofepramine,

Relatively non-selective inhibitors of noradrenaline and serotonin (5-HT)
reuptake

Slow onset (2-4 weeks)

Side effects: dry mouth, blurred vision, constipation, urinary retention (mAChRs); sedation, drowsiness (histamine H1), weight gain. Greater CV risk
Problem for compliance
Toxicity in overdose
Interactions with other drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antidepressants: Inhibitors of monoamine uptake
SSRIs
drug class
examples
side effects

A

SSRIs: Now usual first Line
e.g. sertraline, fluoxetine, paroxetine, citalopram, escitalopram
Similar efficacy to TCAs
Slow onset (2-4 weeks)
Fewer side effects, no anticholinergic, lack of toxicity in overdose, less sedating than TCAs
Side effects: Nausea, sexual dysfunction, insomnia, anxiety
Also used for some anxiety disorders
Washout when switching to be considered – discontinuation symptoms
Suicidal ideation (rare)
Interactions with other drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the available pharmacological therapy?

A

Divided by pharmacological mechanism/target:
Selective serotonin reuptake inhibitors (SSRIs) – typical first line
SNRIs – Serotonin and noradrenaline reuptake inhibitors
Tricyclic antidepressants (TCAs) and 2nd generation cyclics (consider with TCAs)
Monoamine oxidase inhibitors (MAOIs)
NaSSa – noradrenergic and specific serotonergic antidepressant (e.g. mirtazapine)
SARIs – serotonin antagonist and reuptake inhibitor
SMS – Serotonin modulator and stimulator (e.g. Vortioxetine) inhibits reuptake serotonin (SERT) + modulates many 5HT receptors
NRI – Noradenaline reuptake inhibitor (e.g. Reboxetine)

Significant distinguishing features between drugs are typically based on e.g.,:
Antimuscarinic, anti-adrenergic and antihistaminic activity (adverse effects)
Sedative action (not linked to any single transmitter)
Cardiotoxic and/or convulsant action in overdose
Different side effects common for different classes/individual agents
Serotonin syndrome

17
Q

what is Electroconvulsive Therapy

A

Electroconvulsive Therapy (ECT)
Still used, mechanism unknown
Associated with neuronal death
Severe psychotic depression
Bipolar disorder with psychotic symptoms
NICE guidance on ECT: “to be used short term in severe depression where other treatments have failed, especially where suicide is a serious risk”.

18
Q

what are Future Changes/Current Research

A

Ketamine - NMDAR antagonist but may work via other targets. Rapid action.
Esketamine (see BNF) is S(+) enantiomer of ketamine. Now licenced in UK (2020) intranasal antidepressant (specialist use), treatment-resistant depression
TMS – transcranial magnetic stimulation
Psilocybin (mushrooms) – 5HTR agonist, structurally related to 5HT (5HT2AR)
Increasing dopamine

19
Q

Treatment Strategy:New Guidance

A

Step 1: Recognition, assessment
and monitoring

Step 2: For less severe depression
Range of non-pharmacological options (plus SSRIs); based on clinical and cost effectiveness and considerations for implementation
Patient’s preference or experience used as a guide – options to be discussed but with focus on least intrusive and least resource-intensive first
Antidepressant not routinely as first-line unless it is the patient’s preference

Step 3: For more severe depression
Range of non-pharmacological options, anti-depressants (alone) or combined therapies, with first-line a combined option. Based on clinical and cost effectiveness and considerations for implementation
Patient’s preference or experience used as a guide – options to be discussed but aim to match treatment to clinical need and preferences

Step 4: Chronic or psychotic depression, depression with personality disorder:
Referral to specialist services
May include psychological and pharmacological therapy
ECT in certain serious cases
Often combination treatments

20
Q

what are Patient Advice and Care if Prescribed Antidepressants

A

Initiating therapy: Important to highlight
Full effect takes time (e.g. 2-4 weeks)
Important to take as prescribed and continue after remission (e.g. 6 months+)
Potential side effectsand interactions
Risk and nature of discontinuation symptoms with all antidepressants, particularly those with a shorter half-life (e.g. paroxetine and venlafaxine), and how to minimise
Antidepressants are not addictive

Follow-up: Typically see after 2 weeks of initiation then every 2-4 weeks after for 3 months (may then extend)

Changes: Considered if no improvement, significant side effects, patient preference. If switching, many considerations (wash-out, interactions etc.). Can try alternative SSRI or other class. Interactions common between antidepressants.

Switching: Often can direct switch between SSRI/SNRIs (except fluoxetine). For others may need different protocol such as cross-tapering (e.g. SSRI to mirtazapine- less sexual side effects ) or taper/stop*/switch (e.g. SSRI to moclobemide, *1 week)

Consider co-morbidities and adverse effects profile.

21
Q

SSRIs: All potent inhibitors SERT; Sertraline inhibits DAT (less than SERT); (Sigma 1 some agonists, sertraline antagonist). Common side effect e.g.,: nausea & GI disturbance, sexual dysfunction

Sertraline for depression/GAD: 50mg, if required increases 50mg to max 200mg/day with min. week interval

Citalopram for depression: 20mg, if required increase to max 40/day interval 3-4 weeks

Escitalopram for depression/GAD: 10mg then if required increase to max 20/day

Fluoxetine for major depression: 20mg then if required increase up to max 60mg/day with min. 3-4 week interval

Paroxetine for major depression/GAD; 20mg/day (max 50mg)

SNRIs: Potent inhibitors SERT, inhibit NET (duloxetine more than venlafaxine). Common side effects similar SSRIs (though differences for individual agents)

Venlafaxine for major depression/GAD; 75mg then if required increase to max 375mg/day (MD, in 2 divided doses if immediate-release, once for modified) or 225mg/day (GAD). With interval 2+ weeks

Duloxetine for major depression/GAD; 60mg OD; 30mg, if required increase to 60mg/day, 120mg/day max (GAD)

NaSSa: Antagonists of 5-HT2A, 5-HT2C, 5-HT3; a2A/B/C; H1 (potent). Less interactions, less adverse events (e.g. sexual dysfunction) but weight gain and sedation common
Mirtazapine (major depression): 15-30mg 2-4 weeks, bedtime. Can inc. to 45mg/day.

TCAs: Inhibit SERT, NET, antagonists of 5-HT2A, 5-HT2C (& others), H1, H2, a1 adrenergic, mAcR Agonists of Sigma -1 & 2. Common side effect e.g., sedation, anticholinergic effects, hypotension. [Also Lofepramine]
Clomiprimine (depression): 10mg/day then can be increased 30-150mg gradually
Imiprimine (depression): upto 75mg/day (divided doses), can inc. 150-200mg gradually

SARIs: (Serotonin antagonist and Reuptake Inhibitor): Potent antagonist of 5-HT2A, a1; weak SRI and inverse agonist H1. Common side effect e.g., sedation, anticholinergic effects, nausea.
Trazodone for depression, 150mg, can be increased to 300mg (for anxiety initially 75mg)

SMS: Inhibits SERT and modulates several 5HT receptors. Common side effect e.g., abnormal dreams, nausea. Vortioxetine newer agent, can be used when others failed

NRI: Inhibits NET. Reboxetine – an alternative 2nd line agent.

MAOIs/RIMA: subclass of MAOI, reversible inhibitor MAO-A. Safer, less side effects other MAOIs. Example: Moclobemide

A